A RANDOMIZED PHASE 2 STUDY OF ERLOTINIB PLUS PEMETREXED VS ERLOTINIB OR PEMETREXED ALONE AS SECOND-LINE TREATMENT FOR NEVER-SMOKER PATIENTS WITH NON-SQUAMOUS ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Lee, D. H. [1 ]
Lee, J. S. [1 ]
Kim, S. W. [1 ]
Rodrigues Pereira, J. [2 ]
Han, B. [3 ]
Song, X. Q. [4 ]
Wang, J. [5 ]
Kim, H-K. [6 ]
Sahoo, T. P. [7 ]
Digumarti, R. [8 ]
Wang, X. [9 ]
Altug, S. [10 ]
Orlando, M. [11 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
[2] Grp Assistencia Med, Sao Paulo, Brazil
[3] Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Peoples R China
[5] Beijing Tumor Hosp, Beijing, Peoples R China
[6] St Vincent Hosp, Suwon, South Korea
[7] Chirayu Med Coll & Hosp, Bhopal, India
[8] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[9] Eli Lilly & Co, Shanghai, Peoples R China
[10] Eli Lilly & Co, Istanbul, Turkey
[11] Eli Lilly & Co, Buenos Aires, DF, Argentina
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [21] A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer
    Waples, J. M.
    Auerbach, M.
    Boccia, R.
    Wiggans, R. G.
    Steis, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results
    Patel, J. D.
    Hensing, T. A.
    Villafor, V.
    Hart, E.
    Bonomi, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Cost effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small-cell lung cancer (NSCLC) in Taiwan
    Hsia, T. C.
    Chang, G. C.
    Chen, Y. M.
    Lin, M. C.
    Su, W. C.
    Tsai, C. M.
    CM, Tsai
    Yang, L.
    Creeden, J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A325 - A325
  • [24] Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Svaton, Martin
    Minarik, Marek
    Benesova, Lucie
    Bortlicek, Zbynek
    Kucera, Radek
    Topolcan, Ondrej
    [J]. ANTICANCER RESEARCH, 2016, 36 (01) : 447 - 453
  • [25] RANDOMIZED PHASE II STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY PEMETREXED VERSUS PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY PEMETREXED IN ADVANCED NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (LOGIK 0904)
    Shiraishi, Yoshimasa
    Inoue, Koji
    Takeshita, Masafumi
    Harada, Taishi
    Tashiro, Naoki
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Takayama, Koichi
    Ichinose, Yukito
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S403 - S404
  • [26] GGCP041/09: A Galician study of second-line erlotinib in patients with advanced non-squamous non-small cell lung cancer (nsNSCLC).
    Vazquez Estevez, Sergio
    Villanueva Silva, Maria Jose
    Firvida Perez, Jose Luis
    Lazaro Quintela, Martin
    Varela Ferreiro, Silvia
    Huidobro Vence, Gerardo
    Fernandez Calvo, Ovidio
    Campos Balea, Begona
    Casal Rubio, Joaquin
    Areses Manrique, Carmen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] GGCP041/09: A GALICIAN STUDY OF SECOND-LINE ERLOTINIB IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC)
    Vazquez Estevez, S.
    Villanueva Silva, M. J.
    Firvida Perez, J. L.
    Lazaro Quintela, M.
    Varela Ferreiro, S.
    Huidobro Vence, G.
    Fernandez Calvo, O.
    Campos Balea, B.
    Grande Ventura, C.
    Areses, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S67 - S67
  • [28] Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Liang, Jun
    Kang, Jin-Hyoung
    Xiu, Qingyu
    Chen, Yuh-Min
    Blair, Julie Michelle
    Peng, Guangbin
    Linn, Carlos
    Orlando, Mauro
    [J]. LUNG CANCER, 2012, 77 (02) : 346 - 352
  • [29] PEMETREXED MAINTENANCE TREATMENT IN ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Megaiz, Ahlem
    Bousahba, Abdelkader
    Rabah, Aicha
    Zemmour, Amel
    Ahed-Messaoud, Malika
    Ghazli, Soumia
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S588 - S589
  • [30] Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)
    De Boer, R.
    Arrieta, O.
    Gottfried, M.
    Blackhall, F. H.
    Raats, J.
    Yang, C. H.
    Langmuir, P.
    Milenkova, T.
    Read, J.
    Vansteenkiste, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345